Skip to main content
main-content

Oncology

Lung cancer screening benefits increase over time

Doctor_scans

The Multicentric Italian Lung Detection study findings indicate that extending lung cancer screening beyond 5 years boosts the survival benefits associated with early disease detection.

LOXO-195 could be an option for tumors resistant to first-generation TRK inhibitors

DNA_fusion

Early findings point to the antitumor efficacy of the next-generation TRK inhibitor LOXO-195 in patients with NTRK fusion-positive cancers and NTRK resistance mutations acquired during treatment with first-generation agents.

Osimertinib combinations promising for NSCLC patients with acquired resistance to EGFR–TKIs

DNA_cancer cell

Data from the phase Ib TATTON trial suggest that patients with EGFR-mutated non-small-cell lung cancer who have progressed on prior EGFR–tyrosine kinase inhibitor therapy could benefit from adding either the MET inhibitor savolitinib or the MEK inhibitor selumetinib to osimertinib.

ASH 2018: Education program session

Chaired by Professor Jane Apperley with Professor Tim Hughes and Professor Charles Craddock

Held on 1–4 December, 2018 at the San Diego Convention Center, San Diego, California, USA

This education session was chaired by Professor Jane Apperley, from Imperial College London in the UK, and discussed the optimal management of patients with chronic myeloid leukaemia at diagnosis and through disease progression. Using case studies, Apperley and her co-presenters Professor Tim Hughes and Professor Charles Craddock reviewed tyrosine kinase inhibitor treatment decisions that are made in the clinic and when allogeneic stem cell transplantation might be considered.


27-02-2019 | Gallery

Faculty interviews

Scroll below to see interviews with Professors Jane Apperley, Tim Hughes, and Charles Craddock.

Latest news

18-04-2019 | Diabetes | News | Article

Study bolsters evidence for 5 alpha-reductase inhibitor link to type 2 diabetes

Men with benign prostatic hyperplasia undergoing long-term treatment with 5α-reductase inhibitors are significantly more likely to develop type 2 diabetes than those receiving the α-blocker tamsulosin, population-based study data show.

18-04-2019 | Oncology | News | Article

68Ga-PSMA-11 PET shows ‘high accuracy’ for localizing recurrent prostate cancer

Positron emission tomography using 68gallium-labeled ligands of the prostate-specific membrane antigen is accurate, reproducible, and safe in localizing biochemically recurrent prostate cancer, according to the results of a prospective trial.

17-04-2019 | Oncology | News | Article

Conflicting data reported on immunotherapy benefit for older NSCLC patients

The overall survival benefit of immunotherapy in elderly patients with advanced non-small-cell lung cancer is unclear according to two studies with contradictory results presented at the European Lung Cancer Congress 2019 in Geneva, Switzerland.

16-04-2019 | Oncology | News | Article

CheckMate 451: Maintenance immunotherapy fails to improve SCLC survival

Maintenance treatment with nivolumab, either given alone or alongside ipilimumab, does not prolong the overall survival of patients with extensive-stage small-cell lung cancer, the CheckMate 451 investigators have found.

Atezolizumab–Cobimetinib Does Not Improve Advanced CRC Outcomes

PD-L1 blockade – either with or without MEK inhibition – does not appear to be a viable option for patients with locally advanced or metastatic microsatellite-stable colorectal cancer.​​​

Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

Twitter Icon Follow medwireNews

Click here
image credits